Which medications in the drug class Antineoplastics, Antimicrotubular are used in the treatment of Hodgkin Lymphoma?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Antineoplastics, Antimicrotubular

Antimicrotubular antineoplastics disrupt the microtubular network in cells by promoting stabilization and assembly. In addition, these agents block the disassembly of microtubules, thereby preventing cell division, leading to cell death.

Brentuximab vedotin (Adcetris)

Brentuximab is a CD30-directed antibody-drug conjugate (ADC) that consists of chimeric IgG1 antibody cAC10, which is specific for human CD30, bound to the microtubule-disrupting agent monomethyl auristatin E (MMAE, or vedotin). This agent is indicated for treatment of classic Hodgkin lymphoma (cHL) after failure of autologous stem cell transplant (ASCT) or after failure of at least 2 prior multiagent chemotherapy regimens in patients who are not ASCT candidates. It is also indicated as consolidation treatment post-auto-HSCT in patients with high risk for relapse or disease progression. Additionally, brentuximab vedotin is indicated as first-line therapy for previously untreated stage III-IV cHL in combination with chemotherapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!